Last reviewed · How we verify
Université NAZI BONI — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| premix insulin human isophane suspension and insulin human | premix insulin human isophane suspension and insulin human | marketed | ||||
| Humulin N plus Humulin R | Humulin N plus Humulin R | marketed | Insulin combination therapy | Insulin receptor | Diabetes |
Therapeutic area mix
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Eli Lilly and Company · 1 shared drug class
- Hospital Universitario San Ignacio · 1 shared drug class
- Peking University People's Hospital · 1 shared drug class
- Riverside University Health System Medical Center · 1 shared drug class
- Tehran University of Medical Sciences · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Université NAZI BONI:
- Université NAZI BONI pipeline updates — RSS
- Université NAZI BONI pipeline updates — Atom
- Université NAZI BONI pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Université NAZI BONI — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-nazi-boni. Accessed 2026-05-17.